Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Baseline characteristics and the duration of transition period of Secukinumab treatment in moderate to severe Psoriasis.

Trial Profile

Baseline characteristics and the duration of transition period of Secukinumab treatment in moderate to severe Psoriasis.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Sep 2018

At a glance

  • Drugs Secukinumab (Primary)
  • Indications Psoriasis
  • Focus Therapeutic Use
  • Acronyms PROSPECT
  • Most Recent Events

    • 13 Sep 2018 Results presented in a Novartis media release.
    • 13 Sep 2018 According to a Novartis media release, from the study has been presented at the 27th European Academy of Dermatology and Venereology (EADV) Congress.
    • 08 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top